Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3076)	5/13/2015 9:02:10 PM
From: Biotech Jim	Respond to of 3202

Thanks for posting this link, Rick. I am impressed by the results. r/r cHL (classical Hodgkin's Lymphoma) represents an unmet medical need, as are both forms of r/r) relapse/remitting) forms of both cancers mentioned in the abstract. DLBCL (Diffuse Large B Cell Lymphoma) represents about 30% of lymphomas and is usually aggressive compared to the usually indolent CLL (Chronic Lymphocytic Lymphoma) and the usually indolent FL (Follicular Lymphoma). Rituxan and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) is first line therapy for DLBCL typically. (sorry for all the acronyms to lurkers etc, as this is the way these heme/onc docs refer to these diseases and treatments). <the study was expanded to enroll additional cohorts of pts with r/r B-cell malignancies such as DLBCL and cHL, and a phase II study in pts with r/r cHL was initiated> Looks like this might be why INCY is up in after hours, for what that is worth.